Eli Lilly and Company, Novo Nordisk A/S, and Pfizer are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies engaged in the research, development, manufacturing and marketing of medications, vaccines and other therapeutic products. Investors buy these equities to gain exposure to the healthcare sector’s growth potential, with returns often driven by factors such as clinical trial outcomes, regulatory approvals and patent lifecycles. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of LLY stock traded up $3.37 during trading hours on Monday, reaching $765.70. 1,804,734 shares of the company's stock were exchanged, compared to its average volume of 3,794,898. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The stock has a market cap of $725.68 billion, a PE ratio of 62.14, a PEG ratio of 1.08 and a beta of 0.44. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The stock's fifty day moving average price is $775.51 and its two-hundred day moving average price is $800.52.
Read Our Latest Research Report on LLY
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Shares of NYSE:NVO traded up $0.73 during midday trading on Monday, reaching $48.92. The company's stock had a trading volume of 14,994,304 shares, compared to its average volume of 10,763,629. The firm has a market capitalization of $218.41 billion, a PE ratio of 14.44, a P/E/G ratio of 1.46 and a beta of 0.63. Novo Nordisk A/S has a twelve month low of $46.90 and a twelve month high of $139.74. The stock has a fifty day moving average of $69.26 and a 200 day moving average of $72.58. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70.
Read Our Latest Research Report on NVO
Pfizer (PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Shares of NYSE:PFE traded up $0.13 during midday trading on Monday, reaching $23.62. The company's stock had a trading volume of 25,708,769 shares, compared to its average volume of 45,256,961. The stock has a fifty day moving average of $24.36 and a 200 day moving average of $24.55. Pfizer has a twelve month low of $20.92 and a twelve month high of $30.43. The firm has a market capitalization of $134.28 billion, a PE ratio of 17.11, a P/E/G ratio of 0.85 and a beta of 0.52. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64.
Read Our Latest Research Report on PFE
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
